About The Study: Adjuvant nivolumab was not associated with improved disease-free survival in patients with resected non–small cell lung cancer without sensitizing epidermal growth factor receptor and anaplastic lymphoma kinase alterations when given after planned adjuvant chemotherapy and/or radiotherapy.
Corresponding Author: To contact the corresponding author, Jamie E. Chaft, MD, email chaftj@mskcc.org .
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2026.8992)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Media advisory: This study is being presented at the 2026 American Society of Clinical Oncology Annual Meeting.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.8992?guestAccessKey=61a8b5d7-be3b-44df-84c7-9c1d2660be86&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=060126
JAMA